tirzepatide vs topiramate A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults Topiramate and Zepbound Together: Safety

GLP-1 treatment was not statistically significantly different compared to control at reducing the risk of developing dry AMD at one and three years after treatment, but GLP-1 receptor agonists did lower dry AMD risk at five and 10 years after treatment by 9.2% and 14.9%, respectively

Existing Side Effects: Patients already experiencing Wegovy side effects before surgery may sometimes require slower dose reintroduction or closer monitoring during recovery

Barrea L, Verde L, Camajani E, ojat AS, Marina L, Savastano S, Colao A, Caprio M, Muscogiuri G

"So you end up going back to a higher fat mass and a lower muscle mass